Screening CYP3A single nucleotide polymorphisms in a Han Chinese population with a genotyping chip

Pharmacogenomics

Volumn 6, Issue 7, 2005, Pages 731-747

  Liu, Chin Hung ^a   Peck, Konan ^b   Huang, Jin Ding ^a   Lin, Min Shung ^c   Wang, Chin Hsiung ^d   Hsu, Wen Pin ^d   Wang, Hong Wen ^d   Lee, Hui Ling ^a   Lai, Ming Liang ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^c Cathay Medical Center   (Taiwan)

^d Protech Pharmaservices Corporation   (Taiwan)

Author keywords

Allele specific primer extension; Cytochrome P450 3A; Enzyme colorimetric detection; Haplotype; Multiplex PCR; Oligonucleotide microarray; Single nucleotide polymorphisms

Indexed keywords

CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5;

ACCURACY; ARTICLE; BIOTECHNOLOGY; CHINESE; COLORIMETRY; CONTROLLED STUDY; DNA SEQUENCE; ETHNOLOGY; GENE FREQUENCY; GENETIC SCREENING; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; QUALITY CONTROL; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 ENZYME SYSTEM; GENE FREQUENCY; GENETIC SCREENING; HAPLOTYPES; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; POPULATION;

EID: 26944466213     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.6.7.731     Document Type: Article

References (58)

1. Guengerich FP: Cytochrome P450 3A4: regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol. 39, 1-17 (1999).
2. Hesse LM, Venkatakrishnan K, von Moltke LL et al.: CYP3A4 is the major CYP isoform mediating the in vitro hrdroxylation and demethylation of flunitrazepam. Drug Metab. Dispos. 29, 133-140 (2001)
3. Wang RW, Newton JD, Scheri TD et al.: Human cytochrome P450 3A4-catalyed testosterone 6 β-hydroxylation and erythromycin N-demethylation. Competition during catalysis. Drug Metab. Dispos. 25, 502-507 (1997)
4. Li AP, Kaminski DL, Rasmussen A: Substrates of human hepatic cytochrome P450 3A4. Toxicology 104, 1-8 (1995).
5. Evans WE, Relling MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487-491 (1999).
6. Hustert E, Haberl M, Burk O et al.: The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11, 773-779 (2001).
7. Lin YS, Dowling AL, Quigley SD et al.: Coregulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol. Pharmacol. 62, 162-172 (2002).
8. Finta C, Zaphiropoulos PG: The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons. Gene 260, 13-23 (2000).
9. Gellner K, Eiselt R, Hustert E et al.: Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics 11, 111-121 (2001).
10. Thummel KE, Wilkinson GR: In vitro and in vivo drug interactions involving human CYP3A. Annu. Rev. Pharmacol. Toxicol. 38, 389-430 (1998).
11. Ozdemir V, Kalowa W, Tang BK et al.: Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10, 373-388 (2000).
12. Schuetz JD, Beach DL, Guzelian PS: Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics 4, 11-20 (1994).
13. Kuehl P, Zhang J, Lin Y et al.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genet. 27, 383-391 (2001).
14. Sata F, Sapone A, Elizondo G et al.: CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin. Pharmacol. Ther. 67, 48-56 (2000).
15. Rebbeck TR, Jaffe JM, Walker AH et al.: Modification of clinical presentation of prostate tumours by a novel genetic variant in CYP3A4. J. Natl Cancer Inst. 90, 1225-1229 (1998).
16. Ball SE, Scatina J, Kao J et al.: Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin. Pharmacol. Ther. 66, 288-294 (1999).
17. Hsieh KP, Lin YY, Cheng CL et al.: Novel mutations of CYP3A4 in Chinese. Drug Metab. Dispos. 29, 268-273 (2001).
18. Xin X, Luan X, Xiao J et al.: Association study of four activity SNPs of CYP3A4 with the precocious puberty in Chinese girls. Neurosci. Lett. 381, 284-288 (2005).
19. Walker AH, Jaffe JM, Gunasegaram S et al.: Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Hum. Mutat. 12, 289 (1998).
20. Chowbay B, Cumaraswamy S, Cheung YB et al.: Genetic polymorphism in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporine disposition in heart transplant recipients. Pharmacogenetics 13, 89-95 (2003).
21. Chowbay B, Zhou S, Lee EJ et al.: An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: experience in Singapore. Drug Metab. Rev. 37, 327-378 (2005).
22. Cavaco I, Gil JP, Gil-Berglund E et al.: CYP3A4 and MDR1 alleles in a Portuguese population. Clin. Chem. Lab Med. 41, 1345-1350 (2003).
23. Lamba JK, Lin YS, Thummel K et al.: Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 12, 121-132 (2002).
24. Dai D, Tang J, Rose R et al.: Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J. Pharmacol. Exp. Ther. 299, 825-831 (2001).
25. Wen S, Wang H, Ding Y et al.: Screening of 12 SNPs of CYP3A4 in a Chinese population using oligonucleotide microarray. Genet. Test. 8, 411-416 (2004).
26. Hu YF, He Jun, Chen GL et al.: CYP3A5*3 and CYP3A4*18A single nucleotide polymorphisms in a Chinese population. Clin. Chim. Acta 353, 187-192 (2005).
27. Phillips KA, Veenstra DL, Oren E et al.: Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 286, 2270-2279 (2001).
28. Southern EM: DNA chips: analysing sequence by hybridization to oligonucleotides on a large scale. Trends Genet. 12, 110-115 (1996).
29. Hacia JG: Resequencing and mutational analysis using oligonucleotide microarrays. Nature Genet. 21, 42-47 (1999).
30. Ronaghi M, Uhlen M, Nyren P: A sequencing method based on real-time pyrophosphate. Science 281, 363-365 (1998).
31. Syvanen AC: From gels to chips: "minisequencing" primer extension for analysis of point mutations and single nucleotide polymorphisms. Hum. Mutat. 13, 1-10 (1999).
32. Newton CR, Graham A, Heptinstall LE et al.: Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res. 17, 2503-216 (1989).
33. Pastinen T, Kurg A, Metspalu A et al.: Minisequencing: a specific tool for DNA analysis and diagnostics on oligonucleotide arrays. Genome Res. 7, 606-614 (1997).
34. Chou FC, Tzeng SJ, Huang JD: Genetic polymorphism of cytochrome P450 3A5 in Chinese. Drug Metab. Dispos. 29, 1205-1209 (2001).
35. Shih PS, Huang JD: Pharmacokinetics of midazolam and 1′-hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab. Dispos. 30, 1491-1496 (2002).
36. Cheng JY, Chen HH, Kao YS et al.: High throughput parallel synthesis of oligonucleotides with 1536 channel synthesizer. Nucleic Acids Res. 30, e93 (2002).
37. Chen JJ, Wu R, Yang PC et al.: Profiling expression patterns and isolating differentially expressed genes by cDNA microarray system with colorimetry detection. Genomics 51, 313-324 (1998).
38. Lamba JK, Lin YS, Schuetz EG et al.: Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev. 54, 1271-1294 (2002).
39. Vallone PM, Butler JM: AutoDimer: a screening tool for primer-dimer and hairpin structures. Biotechniques 37, 226-231 (2004).
40. SantaLucia J Jr: A unified view of polymer, dumbbell, and oligonucleotide DNA nearest-neighbor thermodynamics. Proc. Natl Acad. Sci. 95, 1460-1465 (1998).
41. Fukushima-Uesaka H, Saito Y, Watanabe H et al.: Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum. Mutat. 23, 100 (2004).
42. Plummer SJ, Conti DV, Paris PL et al.: CTT3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 12, 928-932 (2003).
43. Zeigler-Johnson C, Friebel T, Walker AH et al.: CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer. Cancer Res. 64, 8461-8467 (2004).
44. Garsa AA, McLeod HL, Marsh S et al.: CYP3A4 and CYP3A5 genotyping by Pyrosequencing. BMC Med. Genet. 6, 19 (2005).
45. Eiselt R, Domanski TL, Zibat A et al.: Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 11, 447-458 (2001).
46. Hamzeiy H, Vahdati-Mashhadian N, Edwards HJ et al.: Mutation analysis of the human CYP3A4 gene 5′ regulatory region: population screening using nonradioactive SSCP. Mutat. Res. 500, 103-110 (2002).
47. Wang A, Yu BN, Luo CH et al.: Ile1 18Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients. Eur. J. Clin. Pharmacol. 60, 843-848 (2005).
48. Fukuen S, Fukuda T, Maune H et al.: Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics 12, 331-334 (2002).
49. Chen X, Sullivan PF: Single nucleotide polymorphism genotyping: biochemistry, protocol, cost and throughput. Pharmacogenomics J. 3, 77-96 (2003).
50. Shalon D, Smith SJ, Brown PO: A DNA microarray system for analyzing complex DNA samples using two-color fluorescent probe hybridization. Genome Res. 6, 639-645 (1996).
51. Pease AC, Solas D, Sullivan EJ et al.: Light-generated oligonucleotide arrays for rapid DNA sequence analysis. Proc. Natl Acad. Sci. 91, 5022-5026 (1994).
52. Dubiley S, Kirillov E, Mirzabekov A: Polymorphism analysis and gene detection by minisequencing on an array of gel-immobilized primers. Nucleic Acids Res. 27, e19 (1999).
53. Syvanen AC, Aalto-Setala K, Harju L et al.: A primer-guided nucleotide incorporation assay in the genotyping of apolipoprotein E. Genomics 8, 684-692 (1990).
54. Haff LA, Simirov IP: Single-nucleotide polymorphism identification assays using a thermostable DNA polymerase and delayed extraction MALDI-TOF mass spectrometry. Genome Res. 7, 378-388 (1997).
55. Ayyadevara S, Thaden JJ, Shmookler Reis RJ: Discrimination of primer 3′-nucleotide mismatch by taq DNA polymerase during polymerase chain reaction. Anal. Biochem. 284, 11-18 (2000).
56. van Schaik RH, de Wildt SN, Brosens R et al.: The CYP3A4*3 allele: is it really rare? Clin. Chem. 47, 1104-1106 (2001).
57. Stephens M, Smith NJ, Donnelly P: A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68, 978-989 (2001).
58. Stephens M, Donnelly P: A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am. J. Hum. Genet. 73, 1162-1169 (2003).